StockData
Clene Inc. logo

Clene Inc. (CLNN) stock

CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$3.92−0.08 (-2.00%)

Close on Nov 13, 2026Market cap $50.37MP/E –Yield –

Clene r&d expenses

Research and development expenses are spending on new products and technology.

Clene's R&D Expenses for the twelve months ending Sep 30, 2026 was $13.75M, down 2.3% year over year. For fiscal 2025 it was $14.01M, down 30.1% from the year before. The highest annual figure on record is $31.92M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.01M-30.1%
FY2024Dec 31, 2024$20.06M-24.7%
FY2023Dec 31, 2023$26.66M-16.5%
FY2022Dec 31, 2022$31.92M+12.3%
FY2021Dec 31, 2021$28.42M+86.9%
FY2020Dec 31, 2020$15.20M+59.0%
FY2019Dec 31, 2019$9.56M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.45M+26.6%
Q2 FY2026Jun 30, 2026$3.47M-1.2%
Q1 FY2026Mar 31, 2026$329.00K-77.8%
Q4 FY2025Dec 31, 2025$5.50M-1.2%
Q3 FY2025Sep 30, 2025$3.51M-21.4%
Q2 FY2025Jun 30, 2025$3.51M-15.3%
Q1 FY2025Mar 31, 2025$1.48M-74.8%
Q4 FY2024Dec 31, 2024$5.57M-16.6%
Q3 FY2024Sep 30, 2024$4.47M-25.1%
Q2 FY2024Jun 30, 2024$4.15M-37.3%
Q1 FY2024Mar 31, 2024$5.87M-20.6%
Q4 FY2023Dec 31, 2023$6.67M-27.2%
Q3 FY2023Sep 30, 2023$5.97M-30.4%
Q2 FY2023Jun 30, 2023$6.62M-30.5%
Q1 FY2023Mar 31, 2023$7.40M+20.3%
Q2 FY2022Jun 30, 2022$9.17M+41.6%
Q1 FY2022Mar 31, 2022$8.58M+36.7%
Q4 FY2021Dec 31, 2021$9.52M+113.8%
Q3 FY2021Sep 30, 2021$6.15M+53.9%
Q2 FY2021Jun 30, 2021$6.47M+82.1%
Q1 FY2021Mar 31, 2021$6.28M+96.0%
Q4 FY2020Dec 31, 2020$4.45M–
Q3 FY2020Sep 30, 2020$3.99M–
Q2 FY2020Jun 30, 2020$3.55M–
Q1 FY2020Mar 31, 2020$3.20M–

More Clene figures

See a number that looks wrong?